Obesity: Risk Factor for Cardiotoxicity in Chemotherapy-treated Breast Cancer Patients

Obesity is associated with a three-fold increased risk of cardiotoxicity in chemotherapy-treated patients with early-stage breast cancer, regardless of other predictors of cardiotoxicity, said study.

In chemotherapy-treated patients with breast cancer, being overweight or obesity was found to be the risk factor for cardiotoxicity, stated new study. But the study did not take into account related cardiac risk factors or other classic risk factors of cardiotoxicity produced by anthracycline and trastuzumab (e.g., older age, concomitant chemotherapy or previous radiation therapy, smoking, high blood pressure, or diabetes).

Anthracyclines remain a cornerstone of breast cancer therapy in combination with new-generation targeted drugs such as trastuzumab. Both types of drugs are major culprits in chemotherapy-induced heart disease.

Obesity - Causes, Symptoms, Diagnosis, Complications, Treatment
Obesity is a condition where there is excess accumulation of body fat which poses a risk to the health of the individual. It can affect children and adults.

TOP INSIGHT

Obesity is associated with a three-fold increased risk of cardiotoxicity in chemotherapy-treated patients with early-stage breast cancer, regardless of other predictors of cardiotoxicity.

In a study published in the open-access journal PLOS Medicine, Elisé Kaboré of Centre Georges-François Leclerc and Charles Guenancia of University Hospital, Dijon, France, and colleagues address this gap in knowledge.

As noted by the authors, the results suggest that overweight and obese patients may benefit from careful cardiac screening and follow-up during and after chemotherapy.

The authors examined the association of body mass index and cardiotoxicity using prospective data collected from 2012 to 2014 in the French national breast CANcer TOxicity study (CANTO) of 26 cancer centers. The study included 929 patients with stage I to III breast cancer who were treated with anthracycline and/or trastuzumab.

Recent Advances and the Present Status of Breast cancer Management
The crab that invades the breast is no more a fear factor with all the advancements that medical science and customized protocols can fight breast cancer. the recent developments in the management of breast cancer.

At baseline, nearly half of the study population was overweight or obese. During a mean follow-up period of 22 months following chemotherapy, cardiotoxicity occurred in 29 patients (3.2%). Compared to the normal-weight group, the obese group was more prone to cardiotoxicity (8/466 vs. 9/171; p=0.01), regardless of other predictors of cardiotoxicity.

In addition, cardiotoxicity was independently associated with obesity (OR, 3.02; 95%CI, 1.10-8.25; p=0.03) and trastuzumab administration (OR, 12.12; 51 95%CI, 3.6-40.4; p<0.001). Potential study limitations include selection bias and the relatively short follow-up period. According to the authors, the results should encourage further research into the mechanisms linking obesity to cardiotoxicity, and personalized risk assessment for cardiac complications following cardiotoxic therapies could offer several potential benefits to patients.

Quiz on Chemotherapy Drugs
Chemotherapy involves the administration of medications to fight cancer. Test your knowledge on chemotherapeutic medications by taking this quiz.

Source-Eurekalert

Body Mass Index
The BMI calculator helps you assess your weight indicating if it is normal or if you are underweight or overweight, based on your height.